ReWalk Robotics Reports Fourth Quarter and Year-End 2016 Financial Results - 2016 Full year revenue grows 57% to $5.9 million - - Year-over-year unit placements up 63%; favorable insurance reimburse

ReWalk Robotics Reports Fourth Quarter

and Year-End 2016 Financial Results

- 2016 Full year revenue grows 57% to $5.9 million -

- Year-over-year unit placements up

63%; favorable insurance reimbursement decisions up 122% -

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, February 17, 2017

- ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial

results for the three- and twelve-month periods ended December 31, 2016.

Highlights of and subsequent to the fourth quarter include:

"As ReWalk strives to create

and lead this new industry, we believe we made solid progress in 2016 to advance our goals. More ReWalk devices are being used

at home and in the community than ever before and through our efforts with the U.S. Department of Veterans Affairs, all qualified

veterans now have a path to a ReWalk system. Additionally, we are optimistic that our advanced discussions with large national

coverage providers in the U.S. and Germany will result in broad coverage policies this year, expanding access to potentially thousands

of new users over time," stated Larry Jasinski, Chief Executive Officer.

"We are also focused on opportunities to treat additional

indications and have focused our R&D efforts on our collaboration with Harvard's Wyss Institute to develop a soft exo-suit

designed to meet the needs of stroke victims. As we prepare for our first clinical trial of the soft exo-suit this year, we are

excited by the potential of the technology to serve as a new standard of care in treating stroke patients in the rehabilitation

setting," added Jasinski.

"In 2017, we intend to focus on supporting sales growth,

securing broad reimbursement coverage, and advancing our product developments efforts," concluded Jasinski.

Fourth Quarter 2016 Financial

Total revenue was $1.6 million for

the fourth quarter of 2016, compared to $1.3 million in the fourth quarter of 2015, and up sequentially from $1.4 million in the

third quarter of 2016. 39 ReWalk systems were placed during the fourth quarter of 2016, compared to 25 ReWalk systems placed in

the prior year period, and 23 placed in the third quarter of 2016.

Total operating expenses in the fourth

quarter of 2016 were $7.9 million compared to $7.5 million in the prior year period.

Net loss was $8.5 million for the fourth

quarter of 2016 compared to a net loss of $7.5 million in the fourth quarter of 2015. Non-GAAP net loss for the fourth quarter

was $7.2 million compared with a non-GAAP net loss of $6.7 million in the fourth quarter of 2015.*

*A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

Year-End 2016 Financial Results

Total revenue was $5.9 million for

the year ended December 31, 2016, compared to $3.7 million in 2015. In 2016, 119 ReWalk systems were placed compared to 73 ReWalk

systems placed during 2015.

Full year 2016 operating expenses were

$31.2 million compared to $25.4 million in 2015. In 2017, ReWalk is implementing initiatives to reduce operating expenses including

staff reductions, savings from projects completed at the end of 2016 and other corporate spend.

Net loss for the year ended December

31, 2016 was $32.5 million compared to a net loss of $25.4 million for the full year 2015. Non-GAAP net loss was $27.7 million

for the year compared with a non-GAAP net loss of $22.6 million last year.*

*A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

As of December 31, 2016, ReWalk had

$23.7 million in cash on its balance sheet. In 2016, ReWalk generated approximately $34 million from debt and equity financing

ReWalk management will host its fourth

quarter 2016 and year end conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 66049360.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures

and markets wearable robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the quality

of life for individuals with lower limb disability through the creation and development of market leading robotic technologies.

Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit

http://www.rewalk.com.

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel.

Forward-Looking Statements

In addition to historical information, this press release contains

forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the

U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include

projections regarding ReWalk's future performance and, in some cases, may be identified by words like "anticipate,"

"assume," "believe," "continue," "could," "estimate," "expect,"

"intend," "may," "plan," "potential," "predict," "project,"

"future," "will," "should," "would," "seek" and similar terms or phrases.

The forward-looking statements contained in this press release are based on management's current expectations, which are

subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's

control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking

statements include, among others: ReWalk's expectations regarding future growth, including its ability to increase sales

in its existing geographic markets and to expand to new markets; the conclusion of ReWalk's management, and the opinion of

ReWalk's auditors in their report on the Company's consolidated financial statements for the fiscal year ended December

31, 2016, that there are substantial doubts as to ReWalk's ability to continue as a going concern; ReWalk's ability

to maintain and grow its reputation and to achieve and maintain market acceptance of its products; ReWalk's ability to achieve

reimbursement from third-party payors for its products; ReWalk's ability to repay its secured indebtedness; ReWalk's

expectations as to its clinical research program and clinical results; ReWalk's expectations as to the results of, and the

Food and Drug Administration's potential regulatory actions with respect to, ReWalk's mandatory post-market 522 surveillance

study; the outcome of ongoing shareholder class action litigation relating to ReWalk's initial public offering; ReWalk's

ability to improve its products and develop new products; ReWalk's ability to maintain adequate protection of its intellectual

property and to avoid violation of the intellectual property rights of others; ReWalk's ability to gain and maintain regulatory

approvals; ReWalk's ability to use effectively the proceeds of its 2016 follow-on offering; ReWalk's ability to secure

capital from its at-the-market equity distribution program based on the price range of its ordinary shares and conditions in the

financial markets; ReWalk's ability to maintain relationships with existing customers and develop relationships with new

customers; ReWalk's ability to regain compliance with NASDAQ continued listing requirements; and other factors discussed

under the heading "Risk Factors" in ReWalk's Annual Report on Form 10-K for the year ended December 31, 2016

filed with the U.S. Securities and Exchange Commission and other documents subsequently filed with or furnished to the U.S. Securities

and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or

events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time,

and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly

update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are

prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of

non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers

to as non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three and twelve months ended December 31, 2016 and